♟️ Saturday 4 July 2026 Sat, 4 July 2026

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.

Dealmaking and capital moves drove the week in financials, while one regulatory shock hit hard. PEXA slumped, but Magellan, Euroz Hartleys and several smaller finance names rose on mergers, asset sales and balance-sheet updates.

Speculation ran hottest in junior resources, where drilling hits, study results and funding deals drove some extreme weekly moves. Rare earths, gold and dealmaking set the pace, while several capital raisings and acquisitions produced mixed reactions.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Big swings hit ASX tech as tiny GCM surged, Objective slumped on a Defence contract loss, and DXN fell despite landing new work. Away from the biggest price moves, the week was packed with raisings, acquisitions and fresh AI, quantum and enterprise contract news.